These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31234407)

  • 1. Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies.
    Balestra D; Branchini A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-based therapeutic approaches for coagulation factor deficiencies.
    Pinotti M; Bernardi F; Dal Mas A; Pagani F
    J Thromb Haemost; 2011 Nov; 9(11):2143-52. PubMed ID: 21854538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for bleeding disorders.
    Manno CS
    Curr Opin Hematol; 2002 Nov; 9(6):511-5. PubMed ID: 12394174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autosomal recessive deficiencies of coagulation factors.
    Peyvandi F; Asselta R; Mannucci PM
    Rev Clin Exp Hematol; 2001 Dec; 5(4):369-88. PubMed ID: 11844134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
    Chadwick AC; Wang X; Musunuru K
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inherited thrombophilia.
    Franchini M; Veneri D; Salvagno GL; Manzato F; Lippi G
    Crit Rev Clin Lab Sci; 2006; 43(3):249-90. PubMed ID: 16574555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare coagulation deficiencies.
    Peyvandi F; Duga S; Akhavan S; Mannucci PM
    Haemophilia; 2002 May; 8(3):308-21. PubMed ID: 12010428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multiplexed CRISPR targeting platforms.
    Cao J; Xiao Q; Yan Q
    Drug Discov Today Technol; 2018 Aug; 28():53-61. PubMed ID: 30205881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA Therapeutics: How Far Have We Gone?
    Coutinho MF; Matos L; Santos JI; Alves S
    Adv Exp Med Biol; 2019; 1157():133-177. PubMed ID: 31342441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designer nuclease-mediated gene correction via homology-directed repair in an in vitro model of canine hemophilia B.
    Bergmann T; Ehrke-Schulz E; Gao J; Schiwon M; Schildgen V; David S; Schildgen O; Ehrhardt A
    J Gene Med; 2018 May; 20(5):e3020. PubMed ID: 29608237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells.
    Skvarova Kramarzova K; Osborn MJ; Webber BR; DeFeo AP; McElroy AN; Kim CJ; Tolar J
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28613254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy for Coagulation Disorders.
    Swystun LL; Lillicrap D
    Circ Res; 2016 Apr; 118(9):1443-52. PubMed ID: 27126652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined hereditary coagulation factor deficiencies: familial study of two type-I cases (familial multiple coagulation factor deficiency type I)].
    García Fernández JR; Romero Aguilar A; Moreno Madrid F; de Diego Fernández P; Sánchez Forte M
    An Esp Pediatr; 1999 Apr; 50(4):393-6. PubMed ID: 10356834
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism.
    Kemaladewi DU; Maino E; Hyatt E; Hou H; Ding M; Place KM; Zhu X; Bassi P; Baghestani Z; Deshwar AG; Merico D; Xiong HY; Frey BJ; Wilson MD; Ivakine EA; Cohn RD
    Nat Med; 2017 Aug; 23(8):984-989. PubMed ID: 28714989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
    Diakatou M; Manes G; Bocquet B; Meunier I; Kalatzis V
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.